Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Κυριακή 26 Ιουνίου 2022

Dose of deferasirox correlates with its effects, which differ between low‐risk myelodysplastic syndrome and aplastic anaemia

alexandrossfakianakis shared this article with you from Inoreader
Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia

This study retrospectively evaluated the efficacy, safety and dose–effect relationships of deferasirox (DFX) in patients with low-risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) who were refractory to regular treatment in a real-world setting. We found that a significant decrease in serum ferritin (SF) and an improvement in haematologic parameters, organ function and even overall survival (OS) can be achieved if the accumulated DFX dose reaches a certain level. Patients with low-risk MDS need a higher dose than those with AA.


Abstract

What is known and objective

Patients with low-risk myelodysplastic syndrome (MDS) and aplastic anaemia (AA) often need transfusions, which may accelerate iron overload. The aim of this study was to evaluate the efficacy, safety and dose–effect relationships of deferasirox (DFX) in patients with low-risk MDS and AA who were refractory to regular treatment in a real-world setting.

Methods

Patient data were recorded, and dose–effect relationships of DFX were calculated after the first 6 months. Total annual exposure to DFX was calculated after 12 months and expressed as the accumulated exposure time at a dosage of 20 mg/kg/day.

Results and discussion

Sixty-one patients with low-risk MDS and 51 with AA were enrolled. The minimum dosage of DFX needed for a significant serum ferritin (SF) decrease was 20 mg/kg/day at 6 months, and the minimum accumulation of DFX had to reach 9 months at 20 mg/kg/day by 12 months for patients with low-risk MDS. For patients with AA, the minimum dosage was 10 mg/kg/day at 6 months, and the minimum accumulation had to reach 3 months at 20 mg/kg/day by 12 months. With the same exposure, significant improvements in haematological parameters were also observed in AA. Lower liver enzymes compared with baseline were observed. Gastrointestinal disorders and elevated serum creatinine were the most common side effects. Higher exposure to DFX correlated with longer overall survival (OS).

What is new and conclusion

A significant decrease in SF and an improvement in haematologic parameters, organ function and even OS can be achieved if the accumulated DFX dose reaches a certain level. Patients with low-risk MDS need a higher dose than those with AA.

View on Web

Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

alexandrossfakianakis shared this article with you from Inoreader
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients

Bodyweight and combination with SSRIs are related to bleeding adverse reaction of aspirin. Patients weighted less than 60 kg will be at a higher risk of adverse bleeding events.


Abstract

What is Known and Objectives

Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack. The aim of this study was to evaluate risk factors for bleeding adverse reaction of aspirin in ischemic stroke or transient ischemic attack.

Methods

This retrospective analysis included patients treated with aspirin (100 mg) as a secondary prevention for ischemic stroke or transient ischemic attack. The bleeding events that occurred during the first year were collected, including gastrointestinal, skin, nasal cavity, gum, and urinary tract bleeding events. Then, univariate and multivariate logistic regression analyses were used to identify independent factors associated with bleeding events of aspirin.

Results and Discussion

A total of 578 patients were enrolled in this study, and 58 patients developed bleeding during the first year of secondary prevention. Body weight and combination with selective serotonin reuptake inhibitors were found to be significant risk factors for overall bleeding (p = 0.025 and 0.012). Body weight below 60 kg was a risk factor for overall bleeding and gastrointestinal bleeding events.

What is new and conclusion

Patients weighing less than 60 kg were at increased risk of bleeding with 100 mg aspirin for secondary prevention of cerebral infarction transient ischemic attack.

View on Web

The role of gastrointestinal pathogen PCR testing in liver transplant recipients hospitalized with diarrhea

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

Diarrhea is a common symptom among liver transplant (LT) recipients and can result in significant morbidity. The utility of PCR-based multiplex gastrointestinal (GI) pathogen panels in this population is unknown.

Methods

We assessed incidence, predictors, and outcomes of GI PCR positivity among inpatients who underwent stool pathogen testing with the FilmArray multiplex GI PCR panel at our institution within 1 year following LT from April 2015 to December 2019.

Results

112 patients were identified. 14 (12.5%) had a positive PCR for any pathogen. Escherichia coli (n = 9) and Norovirus (n = 5) were the most common pathogens detected. Recipients with a positive PCR were significantly further from LT (median 74.5 vs 15.5 days, p < 0.01) and tested earlier during hospitalization (median 1.0 vs 9.0 days, p < 0.01). C. difficile was positive in 20.0% of patients with a positive PCR and 11.4% with a negative PCR. CMV viremia was observed in 11.6% of patients, all in the negative PCR group. Following a positive PCR, patients were more likely to have a change in antimicrobial regimen (71.4% vs 28.6%, p = 0.02), a shorter length of stay (median 7.5 vs. 17.5 days, p < 0.01), and a trend toward lower rates of readmission and colonoscopy within 30 days.

Conclusions

In hospitalized LT recipients with diarrhea, GI PCR pathogen identification was associated with the use of targeted antimicrobial therapy and a shorter length of stay. GI PCR testing should be considered early during admission and later in the post-LT period.

This article is protected by copyright. All rights reserved

View on Web

Nanobots to eliminate bacteria in root canals – Nano Dentistry

alexandrossfakianakis shared this article with you from Inoreader

Nanobots in Root Canal Treatment

With millions of Root Canal Treatments being performed every day across the globe, it is important to make sure that Root Canal Treatment is successful in clearing out the bacteria form the Root canals to achieve the purpose of saving an infected tooth using root canal treatment. Disinfection protocol being used today includes mechanical preparation along with use of chemicals such as Sodium Hypochlorite, Hydrogen Peroxide, Chlorhexidine, etc along with Lasers a nd Ultrasonic devices. If these chemicals fail to penetrate the dentinal tubules, accessory canals, etc, proper disinfection cannot be achieved. This is where Nanobots have come into action in eliminating Bacteria in Root Canals which is being termed as - "Nano Dentistry" According to American association of endodontics over 25 millions of root canals are performed annually, over 90% are successful, remaining 10% failures are due to inadequate decontamination of root canal treatment. The dentinal tubules are very small, and the bacteria reside deep in the tissue. correct techniques are not efficient enough to go all the way inside and kill the bacteria. To address these treatment failures, researchers from the "Indian institute of science and nano robotics" company "Theranautilus"  have demonstrated that nano sized robots (nanobots) can effectively kill bacteria in the dentinal tubules. [caption id="attachment_6922" align="alignnone" width="549"]
Nanobots in Root Canal Treatment

Source - https://www.indiatoday.in/science/story/tiny-nanobots-in-teeth-can-kill-bacteria-help-better-dental-treatment-1950064-2022-05-16[/caption] How do Dental Nanobots work in Root Canal Treatment?  Dental Nanobots work by heating up their surface and in turn killing the bacteria in the canals with which they come in contact. So Nanobots use heat to disinfect the canals without the need for chemicals. According to the findings, nanobots were able to penetrate up to 2000um into dentinal tubules, thus achieving a vast improvement in penetration depth compared to laser activation and ultrasonic devices, researchers believe that using the heat to kill the bacteria is the safe alternative to using harsh chemicals agents or antibiotics to decontaminate a root canal. When the nanobots were injected into extracted tooth samples, the nanobots are penetrated deep inside the the dentinal tubules under the control of device that generates a low intensity magnetic field. By manipulating magnetic field, the researches were able to cause the surface of nanobots to generate heat to kill the bacteria nearby. To this end, researchers are currently developing a novel medical device that can be easily placed inside the patient mouth and allow the dentist to inject and manipulate the nanobots inside the teeth during the root canal therapy. Nanobots Or magnetically controlled nanoparticles have been used to trap and move objects using light, which pass through blood and tend to adhere to cancer cells. Researchers at Theranautilus, have used the dental nanoparticles on mice and have concluded them to be safe for use in Biological tissue. The study, titled "Mobile nanobots for prevention of root canal treatment failure", was published online on 28 April 2022 in Advanced Healthcare Materials, ahead of inclusion in an issue. References - Researchers use nanobots to eliminate bacteria in Root canals - Dental Tribune
View on Web

Differential perivascular microglial activation in the deep white matter in vascular dementia developed post‐stroke

alexandrossfakianakis shared this article with you from Inoreader
Differential perivascular microglial activation in the deep white matter in vascular dementia developed post-stroke

Post-stroke patients who develop dementia accrued more perivascular activated CD68+ microglia in the frontal white matter (FWM) This implies activated CD68+ cells are responsible for perivascular inflammation within the gliovascular unit of the FWM


Abstract

With the hypothesis that perivascular microglia are involved as neuroinflammatory components of the gliovascular unit contributing to white matter hyperintensities on MRI and pathophysiology, we assessed their status in stroke survivors who develop dementia. Immunohistochemical and immunofluorescent methods were used to assess the distribution and quantification of total and perivascular microglial cell densities in 68 brains focusing on the frontal lobe WM and overlying neocortex in post-stroke dementia (PSD), post-stroke non-dementia (PSND) and similar age control subjects. We primarily used CD68 as a marker of phagocytic microglia, as well as other markers of microglia including Iba-1 and TMEM119, and the myeloid cell marker TREM2 to assess dementia-specific changes. We first noted greater total densities of CD68+ and TREM2+ cells per mm2 in the frontal WM compared to the overlying cortex across the stroke cases and controls (p =&nbs p;0.001). PSD subjects showed increased percentage of activated perivascular CD68+ cells distinct from ramified or primed microglia in the WM (p < 0.05). However, there was no apparent change in perivascular TREM2+ cells. Total densities of TREM2+ cells were only ~10% of CD68+ cells but there was high degree of overlap (>70%) between them in both the WM and the cortex. CD68 and Iba-1 or CD68 and TMEM119 markers were colocalised by ~55%. Within the deep WM, ~30% of CD68+ cells were co-localised with fragments of degraded myelin basic protein. Among fragmented CD68+ cells in adjacent WM of PSD subjects, >80% of the cells expressed cleaved caspase-3. Our observations suggest although the overall repertoire of perivascular microglial cells is not changed in the parenchyma, PSD subjects accrue more perivascular-activated CD68+ microglia rather than TREM2+ cells. This implies there is a subset of CD68+ cells, which are respon sible for the differential response in perivascular inflammation within the gliovascular unit of the deep WM.

View on Web

Comparative effectiveness and stage‐shift effect of endoscopic exam among newly diagnosed oral cancer patients with different stages in Taiwan

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

Patients with oral cancer are at higher risk of developing second primary esophageal cancer (SPEC) and the consensus for screening strategies remains unclear. This study aimed to examine comparative effectiveness and the stage-shift effect of endoscopic exam among patients with oral cancer.

Method

A population-based longitudinal retrospective observational matched case and control cohort study with at least 5 years follow-up was conducted. We identified 45 457 newly diagnosed patients with oral cancer, 2004–2013, and the eligible patient with oral cancer was 39 401. Propensity score matching was used to match comparable groups, and the two groups (screening vs. nonscreening) was 5941, individually. The study primary endpoints were to compare detection of incident SPEC and the stage-shift effect of endoscopic screening between screened and nonscreened incident oral cancer patients. Cox proportional hazard and competing risk models were analyzed. Statistical analyses were conducted in 2020–2021.

Result

Detection of incident SPEC in the screened group was significantly higher than in the nonscreened group (hazard ratio: 2.92, 95% confidence interval [CI]: 2.29–3.72). The stage-shift effect from endoscopic screening was found overall in patients with oral cancer (odds ratio [OR]: 0.39, 95%CI: 0.21–0.70), in particular in advanced-stage patients (OR: 0.25, 95%CI: 0.11–0.61), but not in early-stage patients (OR: 0.60, 95%CI: 0.26–1.40).

Conclusion

This study confirmed that endoscopic screening achieved early detection of SPEC among patients with oral cancer. To improve the screening stage-shift effect, patients with oral cancer are encouraged to undergo routine endoscopic screening.

View on Web

Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post‐transplant BK and CMV infection

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background

kidney transplantation from HCV-viremic donors to uninfected recipients is associated with excellent short-term outcomes. However, HCV viremia might be associated with an increased risk for post-transplant viral complications.

Methods

We designed a retrospective study of HCV-negative kidney-only transplant recipients between 2018 and 2020. Recipients were grouped into group 1; HCV-negative donors, and group 2; HCV-viremic donors. Patients were matched 1:1 using propensity score. Primary objectives were to compare the incidence of CMV viremia ≥ 200 ml/IU, and BK viremia ≥1000 copies/ml between the groups. Secondary outcomes included group comparison of CMV disease, BK viremia ≥10,000 copies/ml, and one year patient and allograft survival.

Results

The study included 634 patients in group 1, and 71 patients in group 2. 65 pairs of patients were matched. Incidence of CMV viremia (33.3% vs 40.0%, p = 0.4675), and BK viremia (15.9% vs 27.7%, P = 0.1353) did not differ significantly between groups in the matched cohort. Incidence of CMV disease (81.0% Vs 76.9%; p = 1.000), and BK viremia ≥10,000 copies/ml (9.5% vs 16.9%, p = 0.2987) were comparable between groups. There was no difference in the one-year patient or allograft survival between groups.

Conclusion

kidney transplant from HCV-viremic donors is not associated with increased risk for BK or CMV viremia.

This article is protected by copyright. All rights reserved

View on Web

Αρχειοθήκη ιστολογίου